North America Osteoarthritis Therapeutics market was valued at $4,256.0 million in 2025 and is projected to reach $9,551.3 million by 2035, growing at a CAGR of 8.2% during the forecast period (2026–2035). The availability and widespread clinical adoption of established pharmacologic therapies form a core demand driver for the North American osteoarthritis therapeutics market. NSAIDs, corticosteroids, and opioid analgesics remain integral to osteoarthritis treatment algorithms across early, moderate, and advanced disease stages. Their long-standing regulatory approval and inclusion in clinical guidelines support consistent prescribing across primary care, orthopedics, and pain management settings. As osteoarthritis is a chronic and progressive condition, patients often require sustained pharmacologic intervention over extended periods, reinforcing recurring demand. The broad use of first-line oral therapies ensures a stable treatment base, anchoring overall market size and baseline revenue generation.

Global waterjet cutting machines market was valued at $1.5 billion in 2025 and is growing at a CAGR of 4.4% during the forecast period (2026-2035). Technological advancements in cutting head design and pressure control enhance cutting efficiency, enabling manufacturers to work with diverse materials while achieving superior edge quality and minimizing secondary finishing requirements, thereby fostering market growth. For instance, in July 2024, WECJet invested in a new Mach 500 waterjet cutting machine, which utilizes advanced 90000psi Dynamic head cutting technology, making it the fastest waterjet currently available in the global market. This new acquisition enhances WECJet's capabilities, allowing them to cut various materials up to 300mm thick and 3m wide, thanks to an enlarged bed and increased open height for large parts. The company maintains an extensive inventory of materials, including MS/S355, 304, 316 stainless steel, and aluminum in standard thicknesses. Their round-the-clock operations ensure competitive lead times and a 48-hour turnaround for stock materials

Global skin cancer diagnosis and therapeutics market was valued at $14.0 billion in 2025 and is growing at a CAGR of 6.1% during the forecast period (2026-2035). Regulatory approval of the first cell therapy for solid tumors marks a milestone in oncology, broadening treatment avenues from solely hematological cancers to include advanced skin cancers. This development endorses tumor-infiltrating lymphocyte (TIL) approaches, thereby encouraging greater clinical implementation and facilitating market growth through the expansion of treatment pipelines. For instance, in February 2024, FDA approved lifileucel, the first cancer cell therapy for solid tumors, specifically for advanced melanoma. This one-time T-cell therapy, manufactured by Iovance Biotherapeutics and branded as Amtagvi, is indicated for adults with unresectable or metastatic melanoma who have previously received PD-1 inhibitors and, if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.

Global PET-CT market was valued at $2.4 billion in 2025 and is growing at a CAGR of 4.0% during the forecast period (2026-2035). The growing preference for whole-body, single-session imaging is driving the adoption of next-generation PET-CT systems, which enable comprehensive scans from head to thigh in a single acquisition. This enhances diagnostic confidence and improves patient throughput, thereby contributing to market growth. For instance, in November 2025, GE HealthCare received CE Mark approval for its Omni 128cm total body PET/CT system, aimed at enhancing cancer diagnosis and treatment planning. This system offers head-to-thigh imaging in one session, optimizing workflow and reducing scan time and radiation exposure, especially for pediatric patients. It supports both clinical and research endeavors and meets the rising need for advanced imaging solutions with its ultra-high sensitivity and spatial resolution, thereby improving operational efficiency in healthcare systems.

Global pain management devices market was valued at $7,245.4 million in 2025 and is growing at a CAGR of 5.4% during the forecast period (2026-2035). Rising chronic pain prevalence, especially neuropathic pain resulting from trauma and limb loss, is boosting demand for advanced pain management devices, as traditional pharmacological treatments often fail to deliver sustainable long-term relief, thereby reinforcing the need for device-based therapeutic solutions to support market growth. This shift toward targeted, non-pharmacological pain management approaches is increasingly reflected in the commercialization of advanced neuromodulation technologies. For instance, in July 2025, Neuros Medical announced the first commercial implantation of the Altius Direct Electrical Nerve Stimulation System, an FDA-approved device specifically for treating Chronic Post-Amputation Pain in lower limb amputees. 

Global interventional radiology market was valued at $30,336.0 million in 2025 and is growing at a CAGR of 5.1% during the forecast period (2026-2035). Rising adoption of real-time imaging technologies enhances procedural accuracy and minimizes complications by allowing physicians to visualize both patient anatomy and instruments simultaneously. This trend fuels the demand for advanced interventional radiology systems designed for minimally invasive interventions, contributing to market growth. For instance, in July 2025, Cook Medical launched its new Interventional Magnetic Resonance Imaging (iMRI) division, aiming to enhance the way complex procedures are performed, particularly in pediatrics and oncology. This division focuses on creating a range of minimally invasive devices specifically designed for interventional MRI environments, ensuring precision and safety. 

Global anal and colorectal cancer market was valued at $13.6 billion in 2025 and is growing at a CAGR of 4.3% during the forecast period (2026-2035). Accelerated regulatory pathways for innovative oncology therapies targeting high-risk or recurrent cancer populations are fostering investment and expediting clinical development, thereby positively impacting market growth. For instance, in May 2025, the FDA granted fast-track designation to NG-350A for treating mismatch repair proficient locally advanced rectal cancer (LARC). This oncolytic immunotherapy, developed by Akamis Bio, is a T-SIGn therapy delivered intravenously designed to stimulate antigen-presenting cells (APCs) in tumors, enhancing the antitumor immune response. It is being tested alongside chemoradiotherapy in adult patients with LARC at risk for recurrence, as part of the phase 1b FORTRESS trial, which is currently enrolling participants.

Germany digital pathology market was valued at $102.9 million in 2025 and is projected to reach $736.5 million by 2035, growing at a CAGR of 21.9% during the forecast period (2026–2035). Cloud and telepathology solutions are becoming an increasingly important component of the digital pathology ecosystem in Germany. Telepathology enables remote access to high-resolution digital slide images, allowing pathologists to perform consultations and diagnoses regardless of physical location. This capability is particularly valuable for hospitals in rural and underserved regions, where access to specialized pathology expertise may be limited. Cloud-based platforms provide secure, scalable storage for large volumes of whole-slide images and facilitate efficient image sharing across institutions. These solutions also support real-time collaboration among laboratories, hospitals, and external specialists. Additionally, cloud infrastructure enables better workflow management, data integration, and long-term archiving. An increasing number of German hospitals are transitioning from on-premise systems to cloud-driven architectures to improve flexibility and operational efficiency. For instance, Fachklinikum Mainschleife become the first hospital in Germany to migrate its entire IT infrastructure to the cloud using Amazon Web Services (AWS).

Asia-Pacific digital pathology market was valued at $328.1 million in 2025 and is projected to reach $2,736.9 million by 2035, growing at a CAGR of 23.7% during the forecast period (2026–2035). The integration of AI-driven technologies into digital pathology is transforming the landscape of diagnostic practices in the Asia-Pacific region. AI algorithms are being utilized to assist pathologists in analyzing complex pathology images, improving diagnostic accuracy and reducing human error. These technologies enable automated detection of patterns, quantification of tissue characteristics, and identification of potential biomarkers, significantly enhancing the efficiency of diagnosis. AI-driven digital pathology also supports faster processing and higher throughput, enabling laboratories to handle larger case volumes. As a result, healthcare providers in the region are increasingly adopting AI solutions to support personalized medicine, improve patient outcomes, and optimize clinical workflows. This trend is expected to accelerate as AI technology continues to evolve and prove its reliability in clinical settings.

The European asset performance management market reached $660 million in 2025 and is expected to grow to $1,720 million by 2035, registering a CAGR of 10.2% over the forecast period from 2026 to 2035. Across Europe, asset performance management adoption is being driven by enterprise digital transformation and the rising use of connected technologies. Businesses are increasingly turning to cloud computing, artificial intelligence, and real?time data analytics to transform how they manage, monitor, and maintain physical assets. These technologies enable predictive maintenance, reduce operational inefficiencies, and improve reliability across key sectors such as energy and utilities, manufacturing, healthcare, and telecom. As organisations bolster their digital infrastructure, demand for both cloud?based and on?premises APM solutions is expanding, helping firms shift from traditional maintenance models to proactive, data?driven strategies.